Biocon Limited an innovation-led global biopharmaceutical company announced the initiation of the clinical study of Itolizumab in patients with Ulcerative Colitis (UC) in India, in collaboration with Equillium Inc. This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled (adalimumab), two treatment period study to evaluate the safety and efficacy of Itolizumab for the induction of remission in biologics naïve patients with moderate to severely active UC.
source https://www.pharmatutor.org/pharma-news/2022/biocon-initiates-clinical-study-of-itolizumab-for-ulcerative-colitis-in-india
No comments:
Post a Comment